Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @wingyanjoyce, @thetunlab
Contributors ZX performed the experiments and data analyses and drafted the manuscript. YL assisted in data analysis. KY, QL and FZ assisted in sample preparation and experiments. JWYM and LL conducted faecal microbiota transplantation in the clinic. WT and JYLC assisted in clinical data and specimen management. HMT, PC, FKLC and SCN designed and supervised the clinical study, revised the manuscript and provided critical intellectual contribution.
Funding This study received funding support from InnoHK, The Government of Hong Kong, Special Administrative Region of the People’s Republic of China (grant number not available (NA)).
Competing interests FKLC is the co-founder, non-executive Board Chairman and shareholder of GenieBiome Ltd. FKLC is Board Member of CUHK Medical Centre. FKLC has received fees as an advisor and honoraria as a speaker for Eisai Co. Ltd., AstraZeneca, Pfizer Inc., Takeda Pharmaceutical Co., and Takeda (China) Holdings Co. Ltd. FKLC receives patent royalties through his affiliated institutions in the applications of microbiome. SCN is a scientific co-founder and shareholder of GenieBiome Ltd. SCN has served as an advisory board member for Pfizer, Ferring, Janssen, and Abbvie and received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie, and Takeda. SCN has received research grants through her affiliated institutions from Olympus, Ferring, and Abbvie. SCN receives patent royalties through her affiliated institutions in the applications of microbiome. ZX, and WT are part-time employee of GenieBiome Ltd. JYLC received personal fees from GenieBiome Ltd. SCN, FKLC, ZX, QL are named inventors of patent applications held by the CUHK and MagIC that covers the therapeutic and diagnostic use of microbiome related to FMT or obesity.All other co-authors declare no competing interests.
Provenance and peer review Not commissioned; internally peer reviewed.
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.